1428 Results for "

ADC drug

" in MedChemExpress (MCE) Product Catalog:
Products (1428)

1428 Results for "ADC drug" in MCE Product Catalog:

61
61 Publications Verification
Cat. No.: HY-15162
CAS No.: 474645-27-7
Purity:  99.97%
Synonyms: MMAE; SGD-1010
Research Areas:  

Cancer

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-13631E
CAS No.: 1599440-13-7
Purity:  99.94%
Synonyms: MC-GGFG-DXD
Research Areas:  

Cancer

Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-19792
CAS No.: 139504-50-0
Synonyms: DM1; Maytansinoid DM1
Research Areas:  

Cancer

Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-13631D
CAS No.: 1599440-33-1
Purity:  99.30%
Synonyms: Exatecan derivative for ADC
Research Areas:  

Cancer

DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-132254
CAS No.: 1491917-83-9
Purity:  99.13%
Synonyms: IMMU-132
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-132254A
CAS No.: 1491917-83-9
Purity:  96.61%
Synonyms: IMMU-132 (solution)
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-138298
CAS No.: 1826843-81-5
Purity:  98.90%
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-138298A
CAS No.: 1826843-81-5
Purity:  99.58%
Synonyms: T-DXd; DS-8201; DS-8201a
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P99045
CAS No.: 1796566-95-4
Synonyms: HRS7; hRS7

Target:  

ADC Antibodies TROP2

Research Areas:  

Cancer

Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-42973
CAS No.: 1353016-71-3
Target:  

ADC Linkers

Research Areas:  

Cancer

DBCO-NHS ester is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-NHS ester is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15579A
CAS No.: 1415246-68-2
Purity:  99.93%
Synonyms: Monomethylauristatin F hydrochloride
Research Areas:  

Cancer

MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15579
CAS No.: 745017-94-1
Purity:  99.92%
Synonyms: Monomethylauristatin F
Research Areas:  

Cancer

MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15579B
CAS No.: 1799706-65-2
Purity:  99.59%
Synonyms: Monomethylauristatin F sodium
Research Areas:  

Cancer

MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P9921A
CAS No.: 1018448-65-1
Synonyms: Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-128952
CAS No.: 1595275-62-9
Purity:  98.10%
Synonyms: SG3249
Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P9921
CAS No.: 1018448-65-1
Synonyms: Ado-Trastuzumab emtansine; PRO132365; T-DM 1
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-20336
CAS No.: 159857-81-5
Synonyms: Maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate
Target:  

ADC Linkers

Research Areas:  

Others Inflammation/Immunology Cancer

Mc-Val-Cit-PABC-PNP is a cathepsin cleavable linker for antibody-drug conjugates (ADCs) which couples the antibody element to the effecting compound. Mc-Val-Cit-PABC-PNP can be used in the synthesis of ADCs .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-100216
CAS No.: 68181-17-9
Purity:  99.14%
Synonyms: SPDP Crosslinker; Py-ds-Prp-OSu
Target:  

ADC Linkers

Research Areas:  

Cancer

SPDP (SPDP Crosslinker) is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. It is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs) .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-112786
CAS No.: 863971-17-9
Purity:  98.16%
Synonyms: Vc-MMAF
Research Areas:  

Cancer

MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P9985
CAS No.: 2136633-23-1
Synonyms: RC48
Research Areas:  

Cancer

Disitamab vedotin (RC48) is a HER2-targeted antibody-drug conjugate (ADC), formed by conjugation of the humanized anti-HER2 antibody Disitamab (HY-P99854) with drug-linker VcMMAE (HY-15575). VcMMAE consists of a cleavable MC-Val-Cit-PAB linker and the microtubule inhibitor MMAE (HY-15162). After binding to HER2 and undergoing endocytosis, Disitamab vedotin releases MMAE in lysosomes, which further inhibits microtubule assembly, arrests mitosis and induces apoptosis, while also exerting a bystander effect. Disitamab vedotin can be used in studies of HER2-positive breast cancer .
loading...
    loading...